The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis
- PMID: 20399811
- DOI: 10.1016/j.bbamcr.2010.04.005
The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis
Abstract
The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway mediates diverse and important physiological cell functions which include proliferation, differentiation, survival, motility, autophagy, and metabolism. However, dysregulated PI3K/Akt/mTOR signaling has been documented in a wide range of neoplasias, including malignant hematological disorders. It is now emerging that this signaling network plays a key role during normal hematopoiesis, a tightly regulated process resulting in the formation of all blood lineages. Blood cell development encompasses a complex series of events which are mainly regulated by actions of cytokines, a family of extracellular ligands which stimulate many biological responses in a wide array of cell types. Hematopoiesis is strictly dependent on the correct function of the bone marrow microenvironment (BMM), as BMM cells secrete most of the cytokines. Several of these cytokines activate the PI3K/Akt/mTOR signaling network and regulate proliferation, survival, and differentiation events during hematopoiesis. Here, we review the evidence that links the signals emanating from the PI3K/Akt/mTOR cascade with the functions of hematopoietic stem cells and the process of myelopoiesis, including lineage commitment. We then highlight the emerging role played by aberrant PI3K/Akt/mTOR signaling during leukemogenesis.
Copyright 2010 Elsevier B.V. All rights reserved.
Similar articles
-
The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis.Histol Histopathol. 2010 May;25(5):669-80. doi: 10.14670/HH-25.669. Histol Histopathol. 2010. PMID: 20238304 Review.
-
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells.Curr Med Chem. 2011;18(18):2715-26. doi: 10.2174/092986711796011201. Curr Med Chem. 2011. PMID: 21649579 Review.
-
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.Curr Med Chem. 2007;14(19):2009-23. doi: 10.2174/092986707781368423. Curr Med Chem. 2007. PMID: 17691943 Review.
-
Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination.Development. 2016 Sep 1;143(17):3050-60. doi: 10.1242/dev.137075. Development. 2016. PMID: 27578176 Review.
-
Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.Expert Opin Investig Drugs. 2009 Sep;18(9):1333-49. doi: 10.1517/14728220903136775. Expert Opin Investig Drugs. 2009. PMID: 19678801 Review.
Cited by
-
LepR+ niche cell-derived AREG compromises hematopoietic stem cell maintenance under conditions of DNA repair deficiency and aging.Blood. 2023 Nov 2;142(18):1529-1542. doi: 10.1182/blood.2022018212. Blood. 2023. PMID: 37584437
-
PI3-kinase inhibition as a strategy to suppress the leukemic stem cell niche in Ph+ chronic myeloid leukemia.Am J Cancer Res. 2021 Dec 15;11(12):6042-6059. eCollection 2021. Am J Cancer Res. 2021. PMID: 35018241 Free PMC article.
-
Shedding Light on Targeting Chronic Myeloid Leukemia Stem Cells.J Clin Med. 2021 Dec 11;10(24):5805. doi: 10.3390/jcm10245805. J Clin Med. 2021. PMID: 34945101 Free PMC article. Review.
-
PMEPA1/TMEPAI Is a Unique Tumorigenic Activator of AKT Promoting Proteasomal Degradation of PHLPP1 in Triple-Negative Breast Cancer Cells.Cancers (Basel). 2021 Sep 30;13(19):4934. doi: 10.3390/cancers13194934. Cancers (Basel). 2021. PMID: 34638419 Free PMC article.
-
Natural Polyphyllins (I, II, D, VI, VII) Reverses Cancer Through Apoptosis, Autophagy, Mitophagy, Inflammation, and Necroptosis.Onco Targets Ther. 2021 Mar 10;14:1821-1841. doi: 10.2147/OTT.S287354. eCollection 2021. Onco Targets Ther. 2021. PMID: 33732000 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous